Hinge Health Inc. (HNGE)
NYSE NYSE Primary 
Hinge Health, Inc. (HNGE) Q1 2026 Earnings Call Transcript
Hinge Health, Inc. (HNGE) Q1 2026 Earnings Call Transcript
Here's Why You Should Add Hinge Health Stock to Your Portfolio Now
HNGE pairs rapid growth and AI-driven efficiency with rising execution risks as 2026 slowdown, margin pressure, and engagement reliance cloud outlook.
Hinge Health Inc. (HNGE) Up 17.2% Since Last Earnings Report: Can It Continue?
Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Predict a 26.25% Upside in Hinge Health Inc. (HNGE): Here's What You Should Know
The mean of analysts' price targets for Hinge Health Inc. (HNGE) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Hinge Health's AI Moat Might Be Its Patient Movement Data
The cost of healthcare in the United States is on the rise in a big way. In its 2026 healthcare outlook, the Big Four accounting firm PricewaterhouseCoopers (PwC) made strong statements confirming this reality.
How Much Upside is Left in Hinge Health Inc. (HNGE)? Wall Street Analysts Think 38.96%
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Hinge Health Inc. (HNGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Hinge Health, Inc. (HNGE) Q4 2025 Earnings Call Transcript
Hinge Health, Inc. (HNGE) Q4 2025 Earnings Call Transcript
Will Hinge Health Inc. (HNGE) Beat Estimates Again in Its Next Earnings Report?
Hinge Health Inc. (HNGE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hinge Health stock pops 10% after first quarterly report since IPO
Shares of Hinge Health popped after the digital physical therapy company reported quarterly results that beat analysts' estimates for revenue. The company reported quarterly results for the first time since its debut on the New York Stock Exchange in May.
Hinge Health: Huge Growth Potential
I rate Hinge Health a buy due to its patented technology, scalable model, and significant untapped market opportunity. TrueMotion's patented, AI-powered platform and FDA-cleared devices create high barriers to entry and enable rapid, cost-effective growth. HNGE's strong partnerships, high client retention, and integration with major health plans drive predictable revenue and market expansion.
IPO Stock Of The Week: Hinge Health Eyes First Buy Point
IPO Stock Of The Week: Health care leader Hinge Health is approaching its first buy point after its debut in recent week.
Hinge Health: Why Digital Physiotherapy Could Outrun The Competition
Hinge Health is a digital physiotherapy leader with strong technology. Outcomes data shows that 68% pain reduction for patients, and 2.4x ROI for employers. Hinge's competitive edge is the largest dataset, no need for sensors, and integrated pain management. My base case DCF model values HNGE at $43/share (1-year) and $60-$80/share (5-years), with upside from Medicare/Medicaid and international expansion.
